Nasal and pulmonary drug delivery device specialist Valois Pharma is developing expertise and expanding production capacity at its US facility in Congers, New York.
Until now, nasal pump components manufactured at the Congers site were moulded in Europe and assembled at Congers. Now, moulding is being integrated into the Congers site’s manufacturing process, upstream of assembly.
The gain in autonomy of the Congers nasal pump production processes will result in a more reactive supply chain, better adapted to clients’ needs, the company states.
The initial phase of the project, due to be completed by the end of 2009, includes the establishment of a moulding workshop, construction of a new ISO7 cleanroom, and acquisition of injection presses. The second phase will see installation of additional manufacturing capacity to cope with expected market growth.
Overall, the project is expected to last three years, with completion in 2011, and will create an estimated 30 new jobs.
Valois Pharma has four manufacturing facilities worldwide: Congers, in the US, Le Vaudreuil, France, Lugano, Switzerland, and Suzhou, in China.
